A Prospective, Multicenter, Randomized, Open-label Study of 12 Week Duration to Evaluate the Effect of VILDagliptin Added to Insulin on Glycaemic Control in haemoDIALyzed Patients With Type 2 Diabetes: Probe Analysis of CGM

Trial Profile

A Prospective, Multicenter, Randomized, Open-label Study of 12 Week Duration to Evaluate the Effect of VILDagliptin Added to Insulin on Glycaemic Control in haemoDIALyzed Patients With Type 2 Diabetes: Probe Analysis of CGM

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 15 Apr 2016

At a glance

  • Drugs Vildagliptin (Primary) ; Insulin
  • Indications Type 2 diabetes mellitus
  • Focus Therapeutic Use
  • Most Recent Events

    • 08 Apr 2016 Planned End Date changed from 1 Sep 2017 to 1 Jan 2018 as reported by ClinicalTrials.gov record.
    • 08 Apr 2016 Planned primary completion date changed from 1 Jun 2017 to 1 Jan 2018 as reported by ClinicalTrials.gov record.
    • 06 Aug 2015 Planned End Date changed from 1 Jul 2015 to 1 Sep 2017 as per ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top